Prescription attached:-

LIPU MED â COMPLETE CLINICAL PRESCRIPTION REVIEW
Corrected Prescription | Evidence-Based Clinical Working Assessment | MedEx Bangladesh | CDC | NICE | Medical Textbooks
Author: Md.Rafiqul Islam Lipu
Original Prescription Date: 21 April 2025
Clinical Review Date: Thursday, 15 October 2026
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§
āϝā§āύāĻŋāĻĒāĻĨ āĻ āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϤ⧠āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž; āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϝā§āύāĻŋāĻĒāĻĨā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āĻā§āϝāĻžāĻāĻžāĻāύā§āϏāĻŋāϏ, āĻā§āϰāĻžāĻāĻā§āĻŽā§āύāĻŋā§āĻžāϏāĻŋāϏ, āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŦāĻ āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āĻāĻŦāĻ āĻĒā§āϰā§āĻŦā§ āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ Erosion āĻ D&C/ECC-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āϰā§ā§āĻā§āĨ¤
Diagnostic status: Provisional â āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšā§āύāĻŋāĨ¤
Website-Verified Case Number
raiyyantahsan.com-āĻāϰ Medical Blog āĻāĻŦāĻ Gynecology Archive āĻĒā§āύāϰāĻžā§ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
| Numbering | Latest published | New case |
|---|---|---|
| Total Case (TC) | 1371 | 1372 |
| Department Code | 09 | 09 |
| Gynecology Case Number | 45 | 46 |
āϏāϰā§āĻŦāĻļā§āώ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ TC(1371) Pediatric Case āĻāĻŦāĻ Gynecology Case No.45 āĻĒāĻžāĻā§āĻž āĻā§āĻā§āĨ¤ āϤāĻžāĻ āύāϤā§āύ āĻāĻ āĻā§āϏā§āϰ āύāĻŽā§āĻŦāϰ TC(1372).(09).Gynecology Department Case No (46)āĨ¤
Confidence: 0.99
1. Patient Information â āϰā§āĻā§āϰ āϤāĻĨā§āϝ
| Clinical parameter | Prescription finding | āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž | Confidence |
|---|---|---|---|
| Sex | Female | āύāĻžāϰ⧠āϰā§āĻā§ | 0.99 |
| Age | Not clearly documented | āĻŦā§āϏ āύāĻŋāĻļā§āĻāĻŋāϤ āύ⧠| 0.30 |
| Prescription date | 21/04/2025 | ⧍⧧ āĻāĻĒā§āϰāĻŋāϞ ⧍ā§Ļ⧍ā§Ģ | 0.95 |
| Weight | 81 kg | āĻāĻāύ ā§Žā§§ āĻā§āĻāĻŋ | 0.95 |
| BP | Approximately 100/80 mmHg | āĻāύā§āĻŽāĻžāύāĻŋāĻ āϰāĻā§āϤāĻāĻžāĻĒ ā§§ā§Ļā§Ļ/ā§Žā§Ļ | 0.80 |
| Obstetric history | P3, NVD à 3 | āϤāĻŋāύāĻāĻŋ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĒā§āϰāϏāĻŦā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | 0.90 |
| Previous cervical procedure | D&C/ECC | āĻĒā§āϰā§āĻŦā§ āĻāϰāĻžā§ā§/āĻāϰāĻžā§ā§āĻŽā§āĻā§ curettage procedure | 0.85 |
| Laboratory report | Not attached | āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻžāϰ āϰāĻŋāĻĒā§āϰā§āĻ āĻĻā§āĻā§āĻž āĻšā§āύāĻŋ | 1.00 |
Clinical limitation: āϰā§āĻā§āϰ āĻŦā§āϏ, pregnancy status, allergies, pelvic examination āĻāĻŦāĻ laboratory results āύāĻž āĻĨāĻžāĻāĻžā§ definitive infectious diagnosis āĻĻā§āĻā§āĻž āϏāĻŽā§āĻāĻŦ āύā§āĨ¤
2. C/C â Chief Complaints
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻāĻā§āϞ⧠āύāĻŋāĻā§ āϏāĻāĻļā§āϧāĻŋāϤāĻāĻžāĻŦā§ āĻĻā§āĻā§āĻž āĻšāϞā§āĨ¤
C/C 1 â Pain & Burning Sensation in Vagina and Urethra
English: Pain and burning sensation involving the vaginal and urethral region.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻŋāĻĒāĻĨ āĻ āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϰ āĻāĻļāĻĒāĻžāĻļā§ āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻžāĨ¤
Clinical significance:
āĻāĻ āĻāĻĒāϏāϰā§āĻ āύāĻŋāĻŽā§āύā§āĻā§āϤ āϰā§āĻā§ āĻšāϤ⧠āĻĒāĻžāϰā§:
- Vulvovaginitis â āϝā§āύāĻŋāĻĒāĻĨā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
- Bacterial Vaginosis â āϝā§āύāĻŋāϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āĻāĻžāϰāϏāĻžāĻŽā§āϝā§āϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύāĨ¤
- Trichomoniasis â āĻĒā§āϰā§āĻā§āĻā§ā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
- Vulvovaginal Candidiasis â āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
- Cystitis/Urethritis â āĻŽā§āϤā§āϰāĻĨāϞāĻŋ āĻŦāĻž āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
- Cervicitis â āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
- Contact Vulvitis â āϏāĻžāĻŦāĻžāύ āĻŦāĻž āϰāĻžāϏāĻžā§āύāĻŋāĻā§āϰ āĻāĻžāϰāĻŖā§ āĻā§āĻŦāĻžāϞāĻžāĨ¤
Finding confidence: 0.98
C/C 2 â Numbness in Hand
English: Numbness in hand.
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āĻŦāĻž āĻ āύā§āĻā§āϤāĻŋ āĻāĻŽā§ āϝāĻžāĻā§āĻžāĨ¤
āĻāĻāĻŋ āϏāĻŽā§āĻāĻŦāϤ āĻāĻāĻāĻŋ āĻĒā§āĻĨāĻ neurological complaintāĨ¤
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖā§āϰ āĻŽāϧā§āϝ⧠āϰā§ā§āĻā§ peripheral nerve entrapment, vitamin B12 deficiency, diabetes-related neuropathy āĻ āĻĨāĻŦāĻž cervical radiculopathyāĨ¤
āĻļā§āϧ⧠āĻ āĻŦāĻļāĻāĻžāĻŦā§āϰ āĻ āĻāĻŋāϝā§āĻ āĻĨā§āĻā§ peripheral neuropathy āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
Finding confidence: 0.96
C/C 3 â Previous Gynecological Procedure
English: H/O D&C/ECC due to cervical erosion.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āĻŦā§ Cervical Erosion-āĻāϰ āĻāĻžāϰāĻŖā§ D&C/ECC āĻāϰāĻž āĻšā§ā§āĻāĻŋāϞ āĻŦāϞ⧠āĻāϞā§āϞā§āĻ āϰā§ā§āĻā§āĨ¤
āϏāĻŽā§āĻāĻžāĻŦā§āϝ procedure date: 01/03/2025āĨ¤
āϤāĻžāϰāĻŋāĻ āĻāĻŦāĻ procedure-āĻāϰ āĻĒā§āϰā§āĻŖ āĻŦāĻŋāĻŦāϰāĻŖ original records āĻĻāĻŋā§ā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Confidence: 0.82
3. Patient History â āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
A. M/H â Menstrual History
| Parameter | Doctor's note | āĻŦāĻžāĻāϞāĻž |
|---|---|---|
| LMP | 10/04/2025 | āĻļā§āώ āĻŽāĻžāϏāĻŋāĻā§āϰ āĻĒā§āϰāĻĨāĻŽ āĻĻāĻŋāύ ā§§ā§Ļ āĻāĻĒā§āϰāĻŋāϞ ⧍ā§Ļ⧍ā§Ģ |
| Menstrual period | 6 days | āĻŽāĻžāϏāĻŋāĻ āĻā§ āĻĻāĻŋāύ āϏā§āĻĨāĻžā§ā§ āĻšā§ |
| Menstrual cycle | Regular | āύāĻŋā§āĻŽāĻŋāϤ āĻŽāĻžāϏāĻŋāĻ |
| Menstrual flow | Average | āĻŽāĻžāĻāĻžāϰāĻŋ āϰāĻā§āϤāĻĒāĻžāϤ |
| Dysmenorrhoea | Negative | āĻŽāĻžāϏāĻŋāĻāĻāĻžāϞā§āύ āĻŦā§āϝāĻĨāĻžāϰ āĻ āĻāĻŋāϝā§āĻ āύā§āĻ |
Confidence: 0.92
Clinical Interpretation
āĻāĻ menstrual history āĻ āύā§āϝāĻžā§ā§ āϰā§āĻā§āϰ cycle āύāĻŋā§āĻŽāĻŋāϤ āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§āĨ¤ āϤāĻŦā§ cycle length, intermenstrual bleeding, postcoital bleeding āĻāĻŦāĻ contraception history āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
B. O/H â Obstetric History
| Prescription note | Interpretation | āĻŦāĻžāĻāϞāĻž |
|---|---|---|
| MF â 22 years | Married for 22 years, likely | āϏāĻŽā§āĻāĻŦāϤ āĻŦāĻŋāĻŦāĻžāĻšāĻŋāϤ āĻā§āĻŦāύ ⧍⧍ āĻŦāĻāϰ |
| P3 (NVD) +0 | Three vaginal deliveries | āϤāĻŋāύāĻāĻŋ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĒā§āϰāϏāĻŦ |
| ALC â 13 years | Age of Last Child, likely | āϏāĻŽā§āĻāĻŦāϤ āϏāϰā§āĻŦāĻļā§āώ āϏāύā§āϤāĻžāύā§āϰ āĻŦā§āϏ ā§§ā§Š āĻŦāĻāϰ |
Confidence: 0.82
Important: Obstetric notation-āĻāϰ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻ āϰā§āĻĨ āĻŽā§āϞ āύāĻĨāĻŋ āĻĻāĻŋā§ā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
C. Past Gynecological History
H/O Cervical Erosion
Cervical Erosion / Cervical Ectropion â āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ EctropionāĨ¤
Cervical ectropion-āĻ endocervical glandular epithelium āĻŦāĻžāĻāϰā§āϰ āĻĻāĻŋāĻā§ āĻĻā§āĻļā§āϝāĻŽāĻžāύ āĻšā§āĨ¤
āĻāĻāĻŋ āϏāĻŦāϏāĻŽā§ āϏāĻāĻā§āϰāĻŽāĻŖ, āĻā§āώāϤ āĻ āĻĨāĻŦāĻž āĻā§āϝāĻžāύāϏāĻžāϰā§āϰ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āύā§āĨ¤
H/O D&C/ECC
D&C â Dilation and Curettage
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžā§ā§āϰ āĻŽā§āĻ āĻĒā§āϰāϏāĻžāϰāĻŋāϤ āĻāϰ⧠āĻāϰāĻžā§ā§āϰ āĻā§āϤāϰā§āϰ āĻāĻŦāϰāĻŖ āĻĨā§āĻā§ tissue āϏāĻāĻā§āϰāĻš āĻŦāĻž āĻ āĻĒāϏāĻžāϰāĻŖāĨ¤
ECC â Endocervical Curettage
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ canal āĻĨā§āĻā§ tissue āϏāĻāĻā§āϰāĻšāĨ¤
Procedure-āĻāϰ indication āĻ histopathology report āĻĻā§āĻā§āĻž āĻšā§āύāĻŋāĨ¤
Confidence: 0.85
D. D/H â Drug History
Not documented â āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
āĻāĻā§ antibiotic, antifungal, hormonal medicine āĻ āĻĨāĻŦāĻž sedative āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰā§āĻā§āύ āĻāĻŋ āύāĻž āĻāĻžāύāĻž āϝāĻžā§āύāĻŋāĨ¤
E. Allergy History
Not documented â āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
āĻŦāĻŋāĻļā§āώ āĻāϰ⧠macrolide āĻ nitroimidazole allergy āϏāĻŽā§āĻĒāϰā§āĻā§ āĻāĻžāύāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
F. Family History
Not documented â āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
G. O/S/E â Other Systemic Examination
Neurological, cardiovascular, respiratory āĻāĻŦāĻ abdominal examination-āĻāϰ āĻĒā§āϰā§āĻŖ āĻŦāĻŋāĻŦāϰāĻŖ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
4. O/E â On Examination
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻĒāĻžāĻā§āĻž āϝāĻžā§:
Weight: 81 kg
Blood Pressure: Approximately 100/80 mmHg
Clinical Interpretation
Weight: Height āĻāĻžā§āĻž BMI āύāĻŋāϰā§āĻŖā§ āϏāĻŽā§āĻāĻŦ āύā§āĨ¤
Blood Pressure: āĻāĻāĻāĻŋ reading āĻĨā§āĻā§ hypotension āĻŦāĻž hypertension āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
O/G/E â Obstetric/Gynecological Examination
āύāĻŋāĻā§āϰ findings āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝāĻāĻžāĻŦā§ documented āύā§:
| Examination | Finding |
|---|---|
| Vulval examination | Not documented |
| Vaginal discharge assessment | Not documented |
| Speculum examination | Not documented |
| Cervical appearance | Not documented |
| Cervical motion tenderness | Not documented |
| Bimanual examination | Not documented |
Conclusion: āĻŦāϰā§āϤāĻŽāĻžāύ cervical erosion, cervicitis āĻŦāĻž vaginal infection-āĻāϰ objective evidence āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
Confidence: 0.98
5. Doctor's Diagnosis, Investigation, Plan & Advice
A. Doctor's Documented Diagnosis
Current Dx: Not clearly written.
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Cervical Erosion āĻāϞā§āϞā§āĻ āĻĨāĻžāĻāϞā§āĻ āĻāĻāĻŋ āĻĒā§āϰā§āĻŦā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻšāĻŋāϏā§āĻŦā§ āϞā§āĻāĻžāĨ¤
āĻŦāϰā§āϤāĻŽāĻžāύ⧠BV, Trichomoniasis, Cervicitis, UTI āĻ āĻĨāĻŦāĻž Candida infection āύāĻŋāϰā§āĻĻāĻŋāώā§āĻāĻāĻžāĻŦā§ diagnosis āĻāϰāĻž āĻšā§ā§āĻā§âāĻāĻŽāύ āϞā§āĻāĻž āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
Confidence: 0.95
B. Doctor's Investigations
No clearly documented investigations identified.
Urine R/E, Urine Culture, Vaginal Swab, CBC āĻ āĻĨāĻŦāĻž āĻā§āύ⧠laboratory result āύā§āĻāĨ¤
C. Doctor's Plan
āĻāĻŋāĻāĻŋā§āϏāĻ āĻāĻžāϰāĻāĻŋ āĻāώā§āϧ āĻĻāĻŋā§ā§āĻā§āύāĨ¤ āϏāĻāĻļā§āϧāĻŋāϤ medication schedule āĻĒāϰā§āϰ āĻ āĻāĻļā§ āĻĻā§āĻā§āĻž āĻšāϞā§āĨ¤
D. Doctor's Advice
āĻāĻŋāĻā§ āĻ āϏā§āĻĒāώā§āĻ āĻšāĻžāϤ⧠āϞā§āĻāĻž āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āϰā§ā§āĻā§āĨ¤ āϤāĻŦā§ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ investigation advice āĻŦāĻž follow-up instruction āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
Clinical documentation confidence: 0.95
6. Corrected Prescription Transcription
â Table 1 â Verified Prescription Medicines
āĻāĻĒāύāĻžāϰ āϏāĻāĻļā§āϧāύ āĻ āύā§āϝāĻžā§ā§ āĻāĻžāϰāĻāĻŋ āĻāώā§āϧā§āϰ āϏāĻ āĻŋāĻ āύāĻžāĻŽ, strength, dose āĻāĻŦāĻ duration:
| No. | Brand name | Generic name | Strength | Dose | Duration | Total tablets |
|---|---|---|---|---|---|---|
| 1 | Xionil | Bromazepam | 3 mg | 0+0+1 | 15 days | 15 |
| 2 | Zithrox | Azithromycin Dihydrate | 500 mg | 0+0+1 | 7 days | 7 |
| 3 | Riboflavine | Riboflavin (Vitamin B2) | 5 mg | 1+0+1 | 1 month | 60 (assuming 30 days) |
| 4 | Ornil | Ornidazole | 500 mg | 1+0+1 | To be continued | Not defined |
Dose Interpretation
0+0+1: āϏāĻāĻžāϞ⧠āύā§, āĻĻā§āĻĒā§āϰ⧠āύā§, āϰāĻžāϤ⧠āĻāĻāĻāĻŋ tabletāĨ¤
1+0+1: āϏāĻāĻžāϞ⧠āĻāĻāĻāĻŋ āĻāĻŦāĻ āϰāĻžāϤ⧠āĻāĻāĻāĻŋ tabletāĨ¤
To be continued: āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻļā§āώ āϤāĻžāϰāĻŋāĻ āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤ āĻāϰ āĻ āϰā§āĻĨ āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻāĻāĻžāϞ āĻāώā§āϧ āĻāĻžāĻā§āĻž āύāĻŋāϰāĻžāĻĒāĻĻ āĻŦāĻž āĻ āύā§āĻŽā§āĻĻāĻŋāϤâāĻāĻŽāύ āύā§āĨ¤
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Clinical Safety Finding
Ornil 500 mg (Ornidazole) 1+0+1, "to be continued" â āĻāĻ āύāĻŋāϰā§āĻĻā§āĻļāĻāĻŋ āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
āĻāĻžāϰāĻŖ Ornidazole-āĻāϰ āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ neurological adverse effects-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻžā§āĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤ MedEx-āĻāϰ monograph-āĻ peripheral neuropathy āĻāĻŦāĻ āĻāĻŋāĻā§ CNS disorders-āĻā§ contraindication āĻšāĻŋāϏā§āĻŦā§ āĻāϞā§āϞā§āĻ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
āĻāĻ āϰā§āĻā§āϰ āĻāĻā§ āĻĨā§āĻā§āĻ āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦā§āϰ āĻ āĻāĻŋāϝā§āĻ āϰā§ā§āĻā§āĨ¤ āϝāĻĻāĻŋāĻ āĻ āĻŦāĻļāĻāĻžāĻŦ āĻŽāĻžāύā§āĻ peripheral neuropathy āύā§, āϤāĻŦā§āĻ āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ Ornidazole treatment āĻļā§āϰ⧠āĻŦāĻž āĻāĻžāϞāĻŋā§ā§ āϝāĻžāĻā§āĻžāϰ āĻāĻā§ neurological assessment āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ indication āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Medication identification confidence: 1.00 â based on your confirmed corrections.
Clinical safety confidence: 0.98
7. đŠ PRESCRIBED DRUG ANALYSIS â MedEx āĻ āύā§āϝāĻžā§ā§
7.1 Tablet Xionil 3 mg
1. Generic Name
Bromazepam â āĻŦā§āϰā§āĻŽāĻžāĻāĻŋāĻĒāĻžāĻŽāĨ¤
2. Brand Name
Xionil 3 mg Tablet
Manufacturer: SANDOZ (A Novartis Division)
3. MedEx Alternative Brands
MedEx-āĻ āĻĒāĻžāĻā§āĻž āĻāĻāĻ generic-āĻāϰ āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ:
Tenil 3 mg, Siesta 3 mg, Restol 3 mg, Stressnil 3 mgāĨ¤
4. MedEx Therapeutic Class
Benzodiazepine sedatives
āĻŦāĻžāĻāϞāĻž: āĻŦā§āύāĻā§āĻĄāĻžā§āĻžāĻāĻŋāĻĒāĻŋāύ āĻāĻžāϤā§ā§ āĻāĻĻā§āĻŦā§āĻ āĻāĻŽāĻžāύā§āϰ āĻāώā§āϧāĨ¤
5. Pharmacological Class
Benzodiazepine / GABA-A receptor positive allosteric modulatorāĨ¤
6. Use / Purpose of the Drug
Bromazepam āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§:
- Anxiety states â āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻāĻĻā§āĻŦā§āĻāĨ¤
- Acute tension â āϤā§āĻŦā§āϰ āĻŽāĻžāύāϏāĻŋāĻ āĻāĻžāĻĒāĨ¤
- Agitation â āĻ āϏā§āĻĨāĻŋāϰāϤāĻžāĨ¤
- Selected anxiety-associated insomnia â āĻāĻĻā§āĻŦā§āĻāĻāύāĻŋāϤ āĻā§āĻŽā§āϰ āϏāĻŽāϏā§āϝāĻžāĨ¤
- Certain anxiety-related somatic symptoms â āĻāĻĻā§āĻŦā§āĻ-āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻļāĻžāϰā§āϰāĻŋāĻ āĻāĻĒāϏāϰā§āĻāĨ¤
7. Why Doctor Prescribed This Drug in This Patient
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ:
āϰā§āĻā§āϰ genital discomfort-āĻāϰ āϏāĻā§āĻā§ anxiety āĻŦāĻž sleep disturbance āĻĨāĻžāĻāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻāĻĒāϏāϰā§āĻ āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠Bromazepam āĻĻāĻŋā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
āϤāĻŦā§ anxiety āĻŦāĻž insomnia āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠documented āύā§āĨ¤
Prescribing rationale confidence: 0.45
āĻāĻ āĻāώā§āϧ vaginal infection-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϰ⧠āύāĻžāĨ¤
8. Side Effects of Drug
Common: Drowsiness, dizziness, fatigue, muscle weakness, reduced alertnessāĨ¤
Important: Dependence, memory impairment, ataxia āĻāĻŦāĻ withdrawal symptomsāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŽāĻā§āĻŽ āĻāĻžāĻŦ, āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž, āĻĻā§āϰā§āĻŦāϞāϤāĻž, āĻāĻžāϰāϏāĻžāĻŽā§āϝāĻšā§āύāϤāĻž āĻāĻŦāĻ āύāĻŋāϰā§āĻāϰāĻļā§āϞāϤāĻžāϰ āĻā§āĻāĻāĻŋāĨ¤
9. MedEx Link
Xionil 3 mg â MedEx Bangladesh
10. Unit Price, Strip Price & Other Composition
| Parameter | Information |
|---|---|
| Unit price | ā§ŗ5.87 |
| Strip price (10 tablets) | ā§ŗ58.70 |
| 15-tablet nominal cost | ā§ŗ88.05 |
| Original pack (50 tablets) | ā§ŗ293.50 |
| Other composition/strength | āĻāĻ āĻŦā§āϰā§āϝāĻžāύā§āĻĄā§āϰ āĻ āύā§āϝ strength āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋ |
11. Mechanism of Action
Bromazepam GABA-A receptor-āĻāϰ inhibitory effect āĻŦā§āĻĻā§āϧāĻŋ āĻāϰā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻŽāϏā§āϤāĻŋāώā§āĻā§āϰ inhibitory neurotransmission āĻŦāĻžā§āĻŋā§ā§ āϏā§āύāĻžā§ā§āϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻāϤā§āϤā§āĻāύāĻž āĻ āĻāĻĻā§āĻŦā§āĻ āĻāĻŽāĻžā§āĨ¤
12. Drug Indications
Anxiety, agitation, tension-associated symptoms āĻāĻŦāĻ āĻāĻŋāĻā§ psychosomatic complaintsāĨ¤
13. Drug Interactions + Contraindications
Interactions: Alcohol, opioids, hypnotics, sedating antihistamines āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ CNS depressantsāĨ¤
Contraindications: Severe respiratory insufficiency, sleep apnoea, severe hepatic insufficiency āĻāĻŦāĻ hypersensitivityāĨ¤
14. Precautions & Warnings
Dependence āĻāĻŦāĻ withdrawal-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻāĻžā§āĻŋ āĻāĻžāϞāĻžāύā§, machinery operate āĻāϰāĻž āĻāĻŦāĻ alcohol āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ⧠āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
15. Dosage & Administration
Doctor's Prescription:
Xionil 3 mg â 0+0+1 for 15 days.
āĻŦāĻžāĻāϞāĻž: āϰāĻžāϤ⧠āĻāĻāĻāĻŋ āĻāϰ⧠⧧ā§Ģ āĻĻāĻŋāύāĨ¤
āĻāĻāĻŋ historical prescription-āĻāϰ transcription; āĻŦāϰā§āϤāĻŽāĻžāύ āĻāĻŋāĻāĻŋā§āϏāĻž āĻļā§āϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āύā§āĨ¤
16. Pregnancy & Lactation
Pregnancy-āϤ⧠routine use āĻāĻĒāϝā§āĻā§āϤ āύā§āĨ¤ Breastfeeding-āĻāϰ āϏāĻŽā§ āĻā§āĻŋā§ā§ āĻāϞāĻž āĻŦāĻž specialist benefitârisk evaluation āĻĒā§āϰā§ā§āĻāύāĨ¤
Drug information confidence: 0.99
7.2 Tablet Zithrox 500 mg
1. Generic Name
Azithromycin Dihydrate â āĻāĻāĻŋāĻĨā§āϰā§āĻŽāĻžāĻāϏāĻŋāύ āĻĄāĻžāĻāĻšāĻžāĻāĻĄā§āϰā§āĻāĨ¤
2. Brand Name
Zithrox 500 mg Tablet
Manufacturer: Eskayef Pharmaceuticals Ltd.
3. MedEx Alternative Brands
Zitrex 500 mg, Zithrolex 500 mg āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Azithromycin brandsāĨ¤
4. MedEx Therapeutic Class
Macrolides
āĻŦāĻžāĻāϞāĻž: āĻŽā§āϝāĻžāĻā§āϰā§āϞāĻžāĻāĻĄ āĻļā§āϰā§āĻŖāĻŋāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻāĨ¤
5. Pharmacological Class
Azalide antibiotic â Macrolide subclassāĨ¤
6. Use / Purpose of the Drug
Azithromycin āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§ susceptible bacterial infections-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§, āϝā§āĻŽāύ:
Respiratory tract infections: āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āĻļā§āĻŦāĻžāϏāϤāύā§āϤā§āϰā§āϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Skin and soft-tissue infections: āϤā§āĻŦāĻ āĻ āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Chlamydial cervicitis/urethritis: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
7. Why Doctor Prescribed This Drug in This Patient
āϰā§āĻā§āϰ vaginal āĻ urethral burning āĻĨāĻžāĻāĻžā§ āĻāĻŋāĻāĻŋā§āϏāĻ bacterial cervicitis āĻ āĻĨāĻŦāĻž urethritis āϏāύā§āĻĻā§āĻš āĻāϰ⧠Azithromycin āĻĻāĻŋāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
āĻāĻŋāύā§āϤ⧠āĻā§āύ⧠cervical examination āĻŦāĻž Chlamydia testing āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
Prescribing rationale confidence: 0.50
Clinical Warning
Azithromycin 500 mg once daily for seven days is not the CDC standard regimen for uncomplicated chlamydial cervicitis.
CDC-āϰ cervicitis guideline-āĻ doxycycline 100 mg twice daily for seven days recommended regimen āĻāĻŦāĻ azithromycin 1 g single dose alternative regimen āĻšāĻŋāϏā§āĻŦā§ āĻāϞā§āϞā§āĻ āϰā§ā§āĻā§āĨ¤
āĻ āϤāĻāĻŦ, āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻžāϤ āĻĻāĻŋāύā§āϰ course-āĻāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
8. Side Effects of Drug
Common: Nausea, vomiting, abdominal pain, diarrhoeaāĨ¤
Serious: QT prolongation, arrhythmia, severe allergy āĻāĻŦāĻ liver injuryāĨ¤
9. MedEx Link
Zithrox 500 mg â MedEx Bangladesh
10. Unit Price, Strip Price & Other Composition
| Parameter | Information |
|---|---|
| Unit price | ā§ŗ40.00 |
| Strip price (6 tablets) | ā§ŗ240.00 |
| Seven-tablet nominal cost | ā§ŗ280.00 |
| Other strength | 250 mg tablet |
| Other formulation | 200 mg/5 mL suspension |
11. Mechanism of Action
Azithromycin bacterial 50S ribosomal subunit-āĻāϰ āϏāĻā§āĻā§ āϝā§āĻā§āϤ āĻšā§ā§ protein synthesis āĻŦāĻžāϧāĻž āĻĻā§ā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻĒā§āϰā§ā§āĻāύā§ā§ protein āϤā§āϰāĻŋ āĻŦāύā§āϧ āĻāϰ⧠āĻā§āĻŦāĻžāĻŖā§āϰ āĻŦā§āĻĻā§āϧāĻŋ āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻāϰā§āĨ¤
12. Drug Indications
Susceptible respiratory infections, skin infections āĻāĻŦāĻ selected STI-associated infectionsāĨ¤
13. Drug Interactions + Contraindications
Interactions: QT-prolonging drugs, selected anticoagulants āĻāĻŦāĻ antacids-āĻāϰ āϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏāĻŽā§ āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Contraindications: Macrolide hypersensitivity āĻāĻŦāĻ āĻĒā§āϰā§āĻŦā§ Azithromycin-associated severe hepatic reactionāĨ¤
14. Precautions & Warnings
Antibiotic resistance, cardiac arrhythmia risk āĻāĻŦāĻ hepatic impairment āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
15. Dosage & Administration
Doctor's Prescription:
Zithrox 500 mg â 0+0+1 for 7 days.
āĻŦāĻžāĻāϞāĻž: āϰāĻžāϤ⧠āĻāĻāĻāĻŋ āĻāϰ⧠āϏāĻžāϤ āĻĻāĻŋāύāĨ¤
Clinical note: āĻāĻ regimen āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ genital infection-āĻāϰ guideline-standard āĻāĻŋāĻāĻŋā§āϏāĻž āĻšāĻŋāϏā§āĻŦā§ āĻ āύā§āĻŽāĻžāύ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤ Original indication āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
16. Pregnancy & Lactation
āĻĒā§āϰā§ā§āĻāύā§ā§ āĻā§āώā§āϤā§āϰ⧠pregnancy-āϤ⧠Azithromycin āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžā§, āĻāĻŋāύā§āϤ⧠indication āĻ āύā§āϝāĻžā§ā§ āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Breastfeeding-āĻāϰ āĻā§āώā§āϤā§āϰ⧠infant gastrointestinal symptoms āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Drug information confidence: 0.99
7.3 Tablet Riboflavine 5 mg
1. Generic Name
Riboflavin â Vitamin B2āĨ¤
2. Brand Name
Riboflavine 5 mg Tablet
MedEx-āĻ Riboflavine āύāĻžāĻŽā§ āĻāĻāĻžāϧāĻŋāĻ āĻĒā§āϰāϏā§āϤā§āϤāĻāĻžāϰāĻā§āϰ product āϰā§ā§āĻā§āĨ¤
āĻāĻĻāĻžāĻšāϰāĻŖ: Pharmadesh Laboratories Ltd., Indo Bangla Pharmaceutical āĻāĻŦāĻ Bristol Pharmaceuticals Ltd.
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠manufacturer āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
3. MedEx Alternative Brands
Riboflavin, Ribomin, Ribosina, Riboson, RibovitāĨ¤
4. MedEx Therapeutic Class
Vitamin-B preparations
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻŦāĻŋ āĻāĻžāϤā§ā§ āĻĒā§āϰāϏā§āϤā§āϤāĻŋāĨ¤
5. Pharmacological Class
Water-soluble vitamin / Essential micronutrientāĨ¤
6. Use / Purpose of the Drug
Vitamin B2 deficiency āĻĒā§āϰāϤāĻŋāϰā§āϧ āĻ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§āĨ¤
āĻŦāĻŋāĻļā§āώāϤ:
- Cheilosis â āĻ ā§āĻāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āĻĢāĻžāĻāĻžāĨ¤
- Angular stomatitis â āĻŽā§āĻā§āϰ āĻā§āĻŖā§ āĻāĻžāĨ¤
- Glossitis â āĻāĻŋāĻšā§āĻŦāĻžāϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
- Keratitis â āĻāϰā§āύāĻŋā§āĻžāϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
- Seborrhoeic dermatitis â āϤā§āĻŦāĻā§āϰ āĻāĻāĻāĻŋ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āϏāĻŽāϏā§āϝāĻžāĨ¤
7. Why Doctor Prescribed This Drug in This Patient
āϰā§āĻā§āϰ āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āϰā§ā§āĻā§āĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻ nutritional supplementation-āĻāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠Riboflavine āĻĻāĻŋāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
āϤāĻŦā§ Riboflavin deficiency āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻšā§āύāĻŋ āĻāĻŦāĻ Vitamin B2 āĻāĻāĻž unexplained hand numbness-āĻāϰ standard treatment āύā§āĨ¤
āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āĻĨāĻžāĻāϞ⧠vitamin B12 deficiency, diabetes, peripheral nerve entrapment āĻāϤā§āϝāĻžāĻĻāĻŋ āĻĒā§āĻĨāĻāĻāĻžāĻŦā§ āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Prescribing rationale confidence: 0.55
8. Side Effects of Drug
āϏāĻžāϧāĻžāϰāĻŖ āĻŽāĻžāϤā§āϰāĻžā§ āĻŦā§āĻļ āύāĻŋāϰāĻžāĻĒāĻĻāĨ¤
Possible effects: Bright yellow-orange urine āĻāĻŦāĻ āĻāĻā§āĻ āĻŽāĻžāϤā§āϰāĻžā§ gastrointestinal discomfortāĨ¤
9. MedEx Link
Riboflavine 5 mg â MedEx Bangladesh
10. Unit Price, Strip Price & Other Composition
| Parameter | MedEx-listed information |
|---|---|
| Unit price | ā§ŗ0.20âā§ŗ0.28, manufacturer āĻ āύā§āϝāĻžā§ā§ |
| Pharmadesh 500-tablet pack | ā§ŗ140.00 |
| Pharmadesh 1000-tablet pack | ā§ŗ210.00 |
| Strip price | āĻāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ bulk-pack listing-āĻ āύā§āĻ |
| Other brand/formulation | āĻāĻāĻ generic-āĻāϰ 5 mg tablets āĻŦāĻŋāĻāĻŋāύā§āύ āĻĒā§āϰāϏā§āϤā§āϤāĻāĻžāϰāĻā§āϰ |
āĻāĻ āĻŽāĻžāϏ⧠ā§Ŧā§ĻāĻāĻŋ tablet-āĻāϰ nominal cost: āĻĒā§āϰāϏā§āϤā§āϤāĻāĻžāϰāĻ āĻ āύā§āϝāĻžā§ā§ āĻĒā§āϰāĻžā§ ā§ŗ12âā§ŗ16.80āĨ¤
11. Mechanism of Action
Vitamin B2 āĻĨā§āĻā§ FMN āĻāĻŦāĻ FAD āϤā§āϰāĻŋ āĻšā§āĨ¤
āĻāĻā§āϞ⧠cellular energy production, oxidationâreduction reactions āĻāĻŦāĻ normal tissue metabolism-āĻ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻā§āώ⧠āĻļāĻā§āϤāĻŋ āĻā§āĻĒāĻžāĻĻāύ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŦāĻŋāĻĒāĻžāĻā§ā§ āĻāĻžāĻā§ āϏāĻšāĻžā§āϤāĻž āĻāϰā§āĨ¤
12. Drug Indications
Riboflavin deficiency āĻāĻŦāĻ āϏāĻāĻļā§āϞāĻŋāώā§āĻ clinical manifestationsāĨ¤
13. Drug Interactions + Contraindications
Interactions: Phenobarbital, tricyclic antidepressants, anticholinergic medicines āĻ probenecid-āĻāϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ interaction āϰā§ā§āĻā§āĨ¤
Contraindication: Known hypersensitivityāĨ¤
14. Precautions & Warnings
āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāĻžāϞā§āĻāĻžāĻŦā§ āϏāĻšā§āϝ āĻāϰāĻž āĻšā§āĨ¤
āϤāĻŦā§ unexplained numbness-āĻāϰ āĻĒā§āϰāĻā§āϤ āĻāĻžāϰāĻŖ āĻ āύā§āϏāύā§āϧāĻžāύ āĻāϰāĻž āĻāϰā§āϰāĻŋāĨ¤
15. Dosage & Administration
Doctor's Prescription:
Riboflavine 5 mg â 1+0+1 for 1 month.
āĻŦāĻžāĻāϞāĻž: āϏāĻāĻžāϞ⧠āĻāĻāĻāĻŋ āĻ āϰāĻžāϤ⧠āĻāĻāĻāĻŋ āĻāϰ⧠āĻāĻ āĻŽāĻžāϏāĨ¤
Daily total: 10 mg/dayāĨ¤
16. Pregnancy & Lactation
āĻĒā§āϰā§ā§āĻāύā§ā§ nutritional dose-āĻ āϏāĻžāϧāĻžāϰāĻŖāϤ āύāĻŋāϰāĻžāĻĒāĻĻāĨ¤ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ supplementation-āĻāϰ āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Drug information confidence: 0.99
7.4 Tablet Ornil 500 mg
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏāĻāĻļā§āϧāĻŋāϤ āĻāώā§āϧ
1. Generic Name
Ornidazole â āĻ āϰā§āύāĻŋāĻĄāĻžāĻāϞāĨ¤
2. Brand Name
Ornil 500 mg Tablet
Manufacturer: Opsonin Pharma Ltd.
3. MedEx Alternative Brands
āĻāĻāĻ generic-āĻāϰ MedEx-listed brand:
Ornid 500 mg, Ornizol 500 mg, Robic 500 mg, Troniz 500 mg, Xynor 500 mgāĨ¤
4. MedEx Therapeutic Class
Amoebicides, Anti-diarrhoeal antiprotozoal
āĻāĻāĻŋ MedEx-āĻ āĻĒā§āϰāĻĻāϰā§āĻļāĻŋāϤ exact Therapeutic ClassāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāĻŽāĻŋāĻŦāĻž āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒā§āϰā§āĻā§āĻā§ā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧāĨ¤
5. Pharmacological Class
5-Nitroimidazole antiprotozoal and antibacterial agentāĨ¤
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻāĻā§āϰā§āĻāĻŽāĻŋāĻĄāĻžāĻāϞ āĻļā§āϰā§āĻŖāĻŋāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĒā§āϰā§āĻā§āĻā§ā§āĻžāϞ āĻ āĻ ā§āϝāĻžāύāĻžāϰā§āĻŦāĻŋāĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻŦāĻŋāϰā§āĻĻā§āϧ⧠āĻāĻžāϰā§āϝāĻāϰ āĻāώā§āϧāĨ¤
6. Use / Purpose of the Drug
Ornidazole āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§:
1. Trichomoniasis â āĻā§āϰāĻžāĻāĻā§āĻŽā§āύāĻžāϏ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āĻĒā§āϰā§āĻā§āĻā§ā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
2. Bacterial Vaginosis â āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āĻā§āϝāĻžāĻāĻžāĻāύā§āϏāĻŋāϏāĨ¤
āϝā§āύāĻŋāϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ microbiota āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āĻšā§ā§ anaerobic bacteria-āĻāϰ āĻāϧāĻŋāĻā§āϝ āĻšāĻā§āĻžāĨ¤
3. Amoebiasis â āĻ ā§āϝāĻžāĻŽāĻŋāĻŦāĻŋā§āĻžāϏāĻŋāϏāĨ¤
āĻ āύā§āϤā§āϰ āĻŦāĻž āϞāĻŋāĻāĻžāϰ⧠āĻ ā§āϝāĻžāĻŽāĻŋāĻŦāĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
4. Giardiasis â āĻāĻŋā§āĻžāϰā§āĻĄāĻŋā§āĻžāϏāĻŋāϏāĨ¤
Giardia āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
5. Susceptible Anaerobic Infections â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ āĻā§āϏāĻŋāĻā§āύāĻŦāĻŋāĻšā§āύ āĻĒāϰāĻŋāĻŦā§āĻļā§ āĻŦā§āĻĻā§āϧāĻŋ āĻĒāĻžāĻā§āĻž āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
7. Why Doctor Prescribed This Drug in This Patient
āϰā§āĻā§āϰ vaginal burning āĻ genital discomfort āϰā§ā§āĻā§āĨ¤
āĻāĻ āĻāĻĒāϏāϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻŋāĻāĻŋā§āϏāĻ Bacterial Vaginosis āĻ āĻĨāĻŦāĻž Trichomoniasis āϏāύā§āĻĻā§āĻš āĻāϰ⧠Ornidazole āĻĻāĻŋāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
āĻŦāĻŋāĻļā§āώ āĻāϰ⧠Ornidazole-āĻāϰ pharmacological spectrum āĻāĻ āĻĻā§āĻāĻŋ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻĒāϰā§āĻāϝā§āĻā§āϤāĨ¤
āϤāĻŦā§ vaginal discharge, odour, vaginal pH, wet mount āĻ āĻĨāĻŦāĻž Trichomonas NAAT-āĻāϰ āϤāĻĨā§āϝ āύā§āĻāĨ¤
āϏā§āϤāϰāĻžāĻ āĻāώā§āϧāĻāĻŋ āĻĻā§āĻā§āĻžāϰ āĻāĻžāϰāĻŖ āϏāĻŽā§āĻĒāϰā§āĻā§ inference āĻāϰāĻž āϏāĻŽā§āĻāĻŦ āĻšāϞā§āĻ āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
Prescribing rationale confidence: 0.65
Important Clinical Point
Ornidazole Candida infection-āĻāϰ standard treatment āύā§āĨ¤
āĻāĻāĻŋ uncomplicated bacterial cystitis-āĻāϰ first-line treatment-āĻ āύā§āĨ¤
8. Side Effects of Drug
Gastrointestinal: Nausea, vomiting, abdominal discomfortāĨ¤
Neurological: Dizziness, headache, somnolence, ataxia āĻāĻŦāĻ neurological toxicity-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
Haematological: Rare leukopenia, āĻŦāĻŋāĻļā§āώāϤ prolonged treatment-āĻāĨ¤
9. MedEx Link
Ornil 500 mg â MedEx Bangladesh
10. Unit Price, Strip Price & Other Composition
| Parameter | Information |
|---|---|
| Unit price | ā§ŗ7.00 |
| Strip price (10 tablets) | ā§ŗ70.00 |
| Pack price (20 tablets) | ā§ŗ140.00 |
| Other listed strength for Ornil | āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋ |
| Other Ornidazole brands | Ornid, Ornizol, Robic, Troniz, Xynor |
11. Mechanism of Action
Ornidazole susceptible anaerobic organisms-āĻāϰ āĻā§āϤāϰ⧠reduced metabolites āϤā§āϰāĻŋ āĻāϰā§āĨ¤
āĻāĻ metabolites microbial DNA-āĻāϰ structure āĻ function āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻāϰā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŦāĻžāĻŖā§āϰ DNA āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻāϰ⧠āĻā§āĻŦāĻžāĻŖā§āϰ āĻŦā§āĻĻā§āϧāĻŋ āĻ āĻŦā§āĻāĻā§ āĻĨāĻžāĻāĻžāϰ āĻā§āώāĻŽāϤāĻž āύāώā§āĻ āĻāϰā§āĨ¤
12. Drug Indications
Trichomoniasis, bacterial vaginosis, amoebiasis, giardiasis āĻāĻŦāĻ susceptible anaerobic infectionsāĨ¤
13. Drug Interactions + Contraindications
Interactions: Oral anticoagulants, 5-fluorouracil āĻāĻŦāĻ āĻāĻŋāĻā§ āĻ āύā§āϝāĻžāύā§āϝ interacting medicinesāĨ¤
Contraindications: Nitroimidazole hypersensitivity āĻāĻŦāĻ MedEx monograph āĻ āύā§āϝāĻžā§ā§ epilepsy āĻŦāĻž peripheral neuropathy-āϏāĻš āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ neurological disordersāĨ¤
14. Precautions & Warnings
āĻāĻāĻŋ āĻāĻ āĻā§āϏā§āϰ āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ safety considerationāĨ¤
āĻāĻžāϰāĻŖ āϰā§āĻā§āϰ āĻšāĻžāϤ⧠numbness āĻāĻā§ āĻĨā§āĻā§āĻ documentedāĨ¤
āĻĻā§āϰā§āĻāĻĻāĻŋāύ Ornidazole āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠neurological adverse effects āĻāĻŦāĻ āĻŦāĻŋāϰāϞ haematological complications āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻ āϤāĻāĻŦ, āϰā§āĻā§āϰ neurological symptoms āĻŽā§āϞā§āϝāĻžā§āύ āύāĻž āĻāϰ⧠indefinite treatment āϏāĻŽāϰā§āĻĨāύāϝā§āĻā§āϝ āύā§āĨ¤
15. Dosage & Administration
Doctor's Prescription:
Ornil 500 mg â 1+0+1, To be continued.
āĻŦāĻžāĻāϞāĻž: āϏāĻāĻžāϞ⧠āĻāĻāĻāĻŋ āĻāĻŦāĻ āϰāĻžāϤ⧠āĻāĻāĻāĻŋ; āĻāϤāĻĻāĻŋāύ āĻāϞāĻŦā§ āϤāĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āύā§āĨ¤
Daily total: 1000 mg/dayāĨ¤
MedEx Dose Comparison
MedEx-listed indication-specific regimens-āĻāϰ āĻāĻĻāĻžāĻšāϰāĻŖ:
Trichomoniasis: 500 mg twice daily for five days āĻ āĻĨāĻŦāĻž listed alternative regimenāĨ¤
Bacterial Vaginosis: 500 mg once daily for five āĻĨā§āĻā§ āϏāĻžāϤ āĻĻāĻŋāύ āĻ āĻĨāĻŦāĻž listed alternative regimenāĨ¤
āĻāĻā§āϞ⧠āĻŽā§āϞ prescription-āĻāϰ āύāϤā§āύ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āύā§āĨ¤ āĻŦāĻŋāĻāĻŋāύā§āύ āĻāύā§āϤāϰā§āĻāĻžāϤāĻŋāĻ guideline-āĻ āĻ āύā§āϝ nitroimidazole, āĻŦāĻŋāĻļā§āώāϤ metronidazole-based regimens āĻ āĻā§āϰāĻžāϧāĻŋāĻāĻžāϰ āĻĒāĻžā§āĨ¤
Critical Clinical Interpretation
"To be continued" is not an acceptable standalone duration for long-term ornidazole therapy without a clearly documented indication and review plan.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻ, āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻ stop date āĻāĻžā§āĻž āĻĻā§āϰā§āĻāĻĻāĻŋāύ Ornidazole āĻāĻžāϞāĻžāύ⧠āĻāĻāĻŋāϤ āύā§āĨ¤
16. Pregnancy & Lactation
Pregnancy āĻ lactation-āĻ āĻĒāϰā§āϝāĻžāĻĒā§āϤ clinical safety data āϏā§āĻŽāĻŋāϤāĨ¤
āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠specialist benefitârisk assessment āĻĒā§āϰā§ā§āĻāύāĨ¤
Drug information confidence: 0.99
Case-specific treatment-duration safety concern: 0.98
8. 𩷠Bangladesh Clinical Practice â Vulvovaginitis Medicines Used by Doctors
āĻāĻāĻžāύ⧠āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āĻāĻĒāϞāĻŦā§āϧ āĻ āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ āĻāώā§āϧāĻā§āϞ⧠āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ āĻĻā§āĻāĻžāύ⧠āĻšā§ā§āĻā§āĨ¤
āĻāĻā§āϞ⧠āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻāώā§āϧ āύā§āĨ¤ āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāĻā§āĻžāϰ āĻĒāϰ āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻāĻāĻāĻŋ āĻāĻĒāϝā§āĻā§āϤ treatment pathway āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšā§āĨ¤
Table 2 â Disease-Specific Medicine Options
| No. | Generic | Brand example | MedEx Therapeutic Class | Pharmacological Class | Clinical use |
|---|---|---|---|---|---|
| 1 | Clotrimazole | Afun VT 200 mg | Drugs used in Vaginal and Vulval condition, Topical Antifungal preparations | Imidazole antifungal | Confirmed vaginal candidiasis |
| 2 | Fluconazole | Flugal 150 mg | Systemic antifungal medicine | Triazole antifungal | Selected nonpregnant candidiasis |
| 3 | Metronidazole | Filmet 400 mg | Amoebicides, Anti-diarrhoeal antiprotozoal | Nitroimidazole | Bacterial vaginosis / Trichomoniasis |
| 4 | Ornidazole | Ornil 500 mg | Amoebicides, Anti-diarrhoeal antiprotozoal | Nitroimidazole | Selected anaerobic/protozoal infection |
| 5 | Nitrofurantoin | Nitrofur SR 100 mg | Systemic Urinary Anti-infective | Nitrofuran antibiotic | Susceptible lower UTI |
| 6 | Fosfomycin Trometamol | Monuril 3 g | Intracellular antibiotic | Phosphonic acid antibiotic | Selected uncomplicated cystitis |
| 7 | Azithromycin | Zithrox 500 mg | Macrolides | Azalide antibiotic | Selected bacterial cervicitis |
| 8 | Riboflavin | Riboflavine 5 mg | Vitamin-B preparations | Water-soluble vitamin | Vitamin B2 deficiency |
Clinical note: āĻāĻāĻžāύ⧠MedEx-āĻāϰ Therapeutic Class āĻāĻŦāĻ pharmacological class āĻāϞāĻžāĻĻāĻž āϰāĻžāĻāĻž āĻšā§ā§āĻā§āĨ¤ Drug classes-āĻāϰ āĻāĻŋāĻā§ āύāĻžāĻŽ MedEx-āĻāϰ āύāĻŋāĻāϏā§āĻŦ classification āĻ āύā§āϝāĻžā§ā§ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§āĨ¤
Table 3 â Bangladesh Drug Price & MedEx Links
| No. | Drug | Unit price | Strip/pack price | MedEx |
|---|---|---|---|---|
| 1 | Afun VT 200 mg | ā§ŗ20.06 | 3 tablets: ā§ŗ60.18 | View |
| 2 | Flugal 150 mg | ā§ŗ22.14 | 10 capsules: ā§ŗ221.40 | View |
| 3 | Filmet 400 mg | ā§ŗ1.70 | 10 tablets: ā§ŗ17.00 | View |
| 4 | Ornil 500 mg | ā§ŗ7.00 | 10 tablets: ā§ŗ70.00 | View |
| 5 | Nitrofur SR 100 mg | ā§ŗ26.00 | 10 capsules: ā§ŗ260.00 | View |
| 6 | Monuril 3 g | ā§ŗ350.00 | One sachet: ā§ŗ350.00 | View |
| 7 | Zithrox 500 mg | ā§ŗ40.00 | 6 tablets: ā§ŗ240.00 | View |
| 8 | Riboflavine 5 mg | ā§ŗ0.20â0.28 | Bulk packs; manufacturer-dependent | View |
Prices: MedEx-āĻ āĻĒā§āϰāĻĻāϰā§āĻļāĻŋāϤ āĻŽā§āϞā§āϝ; āĻŦāĻžāĻāĻžāϰ⧠āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical Selection â āĻā§āύ āϰā§āĻā§ āĻā§āύ āĻāώā§āϧ?
Confirmed Candida Vaginitis: Clotrimazole vaginal preparations āĻ āĻĨāĻŦāĻž āĻāĻĒāϝā§āĻā§āϤ nonpregnant āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠fluconazoleāĨ¤
Confirmed Bacterial Vaginosis: Metronidazole-based guideline regimen āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒā§āϰāĻĨāĻŽ āϏāĻžāϰāĻŋāϰ āĻŦāĻŋāĻāϞā§āĻĒāĻā§āϞā§āϰ āĻāĻāĻāĻŋāĨ¤
Confirmed Trichomoniasis: CDC āĻ āύā§āϝāĻžā§ā§ āύāĻžāϰā§āĻĻā§āϰ āĻāύā§āϝ metronidazole 500 mg twice daily for seven days recommendedāĨ¤
Confirmed Acute Uncomplicated Cystitis: Nitrofurantoin āĻ āĻĨāĻŦāĻž āĻ āύā§āϝ guideline-supported antibiotic, renal function āĻ bacterial susceptibility āĻ āύā§āϝāĻžā§ā§āĨ¤
Selected Cervicitis: STI testing āĻ risk āĻ āύā§āϝāĻžā§ā§ doxycycline āĻŦāĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ alternative regimenāĨ¤
Clinical confidence: 0.97
9. đ¨ MY CLINICAL WORKING ASSESSMENT
9.1 đĒ Prescription-Ready Provisional Diagnosis
Vulvovaginal and Urethral Burning/Pain of Undetermined Etiology â Suspected Vulvovaginitis; Evaluate for Bacterial Vaginosis, Trichomoniasis, Cervicitis and Acute Cystitis. Associated Hand Paresthesia. H/O Cervical Erosion and D&C/ECC.
āĻŦāĻžāĻāϞāĻž Diagnosis
āϝā§āύāĻŋāĻĒāĻĨ āĻ āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϤ⧠āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž, āϝāĻžāϰ āĻāĻžāϰāĻŖ āĻāĻāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϝā§āύāĻŋāĻĒāĻĨā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āϰā§ā§āĻā§āĨ¤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āĻā§āϝāĻžāĻāĻžāĻāύā§āϏāĻŋāϏ, āĻā§āϰāĻžāĻāĻā§āĻŽā§āύāĻŋā§āĻžāϏāĻŋāϏ, āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻ āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻĒāϰā§āĻā§āώāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āϰā§ā§āĻā§ āĻāĻŦāĻ āĻĒā§āϰā§āĻŦā§ Cervical Erosion āĻ D&C/ECC-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻā§āĨ¤
Clinical Confidence
| Working assessment | Confidence |
|---|---|
| Vaginal/urethral burning and pain documented | 0.98 |
| Hand numbness documented | 0.96 |
| Previous cervical procedure documented | 0.85 |
| Vulvovaginitis possible | 0.75 |
| Bacterial vaginosis possible | 0.60 |
| Trichomoniasis possible | 0.50 |
| Cervicitis possible | 0.50 |
| Acute cystitis possible | 0.55 |
| Infection confirmed by laboratory testing | Not established |
Interpretation: āĻāĻ scores clinical certainty-āĻāϰ āĻāύā§āĻŽāĻžāύāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ; calibrated diagnostic probability āύā§āĨ¤
9.2 đĒ Specific Specialist Department / Doctor Referral
Primary Referral
Consultant Obstetrician & Gynaecologist
āĻŦāĻžāĻāϞāĻž: āϏā§āϤā§āϰā§āϰā§āĻ āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
Referral indication: Vaginal and urethral burning, suspected vulvovaginitis, assessment for genital/urinary infection, prior cervical procedure history āĻāĻŦāĻ treatment reviewāĨ¤
Secondary Referral
Medicine Specialist / Neurologist
āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āĻāϞāϤ⧠āĻĨāĻžāĻāϞ⧠āĻŦāĻž neurological findings āĻĒāĻžāĻā§āĻž āĻā§āϞā§āĨ¤
Urologist
Recurrent UTI āĻ āĻĨāĻŦāĻž persistent unexplained urinary symptoms āĻĨāĻžāĻāϞā§āĨ¤
9.3 đ§ Clinical Diagnosis â Severity / Category / Complications
Disease category: Genitourinary symptom complex with suspected vulvovaginal inflammationāĨ¤
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻŋāĻĒāĻĨ āĻ āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϰ āĻāĻĒāϏāϰā§āĻāϏāĻš āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āϏāĻŽāϏā§āϝāĻžāĨ¤
Severity: UndeterminedāĨ¤
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āϤā§āĻŦā§āϰāϤāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖā§āϰ āĻāύā§āϝ āĻĒāϰā§āϝāĻžāĻĒā§āϤ āϤāĻĨā§āϝ āύā§āĻāĨ¤
Complications: None documentedāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻā§āύ⧠complication āύāĻĨāĻŋāϤ⧠āĻāϞā§āϞā§āĻ āύā§āĻ; āϤāĻŦā§ āĻĒāϰā§āϝāĻžāĻĒā§āϤ examination āĻāĻžā§āĻž āĻ āύā§āĻĒāϏā§āĻĨāĻŋāϤāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
10. đ§ Doctor's Dx vs đŠ My Clinical Dx
đ§ DOCTOR'S DOCUMENTED DIAGNOSIS
No clearly written definitive current diagnosis.
āĻĄāĻžāĻā§āϤāĻžāϰ Cervical Erosion āĻ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠procedure-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύāĨ¤
āĻāώā§āϧā§āϰ āĻŽāϧā§āϝ⧠Azithromycin āĻ Ornidazole āĻĨāĻžāĻāĻžā§ bacterial/protozoal infection-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĻā§āĻā§āĻžāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ āĻāĻāĻŋ prescribing intent-āĻāϰ inference, diagnosis-āĻāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĨ¤
đŠ MY CLINICAL WORKING DIAGNOSIS
Suspected Vulvovaginitis with Vaginal/Urethral Burning; R/O Bacterial Vaginosis, Trichomoniasis, Cervicitis and Acute Cystitis; Associated Hand Paresthesia.
Diagnosis Comparison
| Parameter | Doctor | My Assessment | Comparison |
|---|---|---|---|
| Vaginal burning | Documented | Included | đĸ Similar |
| Urethral discomfort | Documented | Included | đĸ Similar |
| Hand numbness | Documented | Included | đĸ Similar |
| Cervical erosion | Past history | Past history | đĸ Similar |
| Current bacterial infection | Not confirmed | Possible | đ Cannot establish agreement |
| BV / Trichomoniasis | No explicit diagnosis | Rule out | đ Additional differential |
| UTI | No explicit diagnosis | Rule out | đ Additional differential |
| Definitive diagnosis | Not documented | Not established | đĸ Similar evidence status |
Final Comparison Result
Doctor's diagnosis āĻāĻŦāĻ My diagnosis āĻāĻāĻ āĻāĻŋ āύāĻž?
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻāĻāĻāĻŋ āϏā§āĻĒāώā§āĻ āĻŦāϰā§āϤāĻŽāĻžāύ diagnosis āύāĻž āĻĨāĻžāĻāĻžā§ āϏāĻŽā§āĻĒā§āϰā§āĻŖ agreement āĻ āĻĨāĻŦāĻž disagreement āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
āϤāĻŦā§ āϰā§āĻā§āϰ documented symptoms-āĻāϰ āϏāĻā§āĻā§ working diagnosis āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
āĻŽā§āϞ āĻĒāĻžāϰā§āĻĨāĻā§āϝ: āĻāĻŽāĻžāϰ āĻŽā§āϞā§āϝāĻžā§āύ⧠āĻāĻāĻžāϧāĻŋāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ āĻĒā§āĻĨāĻ āĻāϰāĻž āĻšā§ā§āĻā§ āĻāĻŦāĻ diagnosis āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāϰ investigation plan āϝā§āĻā§āϤ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
Comparison confidence: 0.97
11. Definition â Disease Overview
Vulvovaginitis
Definition: Inflammation or irritation of the vulva and vaginaāĨ¤
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻŋāϰ āĻŦāĻžāĻāϰā§āϰ āĻ āĻāĻļ āĻ āϝā§āύāĻŋāĻĒāĻĨā§ āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āĻā§āĻŦāĻžāϞāĻžāĨ¤
āĻāĻāĻŋ bacterial, fungal, protozoal āĻ āĻĨāĻŦāĻž noninfectious āĻāĻžāϰāĻŖā§ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Bacterial Vaginosis
Definition: Vaginal dysbiosis characterized by reduced lactobacilli and increased anaerobic bacteriaāĨ¤
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻŋāϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻĒāĻāĻžāϰ⧠āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āĻāĻŽā§ āĻāĻŋā§ā§ āĻ āύā§āϝ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻāϧāĻŋāĻā§āϝ āĻšāĻā§āĻžāĨ¤
Trichomoniasis
Definition: Infection caused by Trichomonas vaginalisāĨ¤
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āĻĒā§āϰā§āĻā§āĻā§ā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Cervicitis
Definition: Inflammation of the cervixāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
Acute Cystitis
Definition: Infection or inflammation of the urinary bladderāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Reference: CDC STI Guidelines, 2021āĨ¤
12. Etiology & Pathophysiology
A. Bacterial Vaginosis
Vaginal lactobacilli āĻāĻŽā§ āĻāĻŋā§ā§ anaerobic bacteria āĻŦā§āĻĻā§āϧāĻŋ āĻĒā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻāϤ⧠vaginal pH āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āĻšā§ āĻāĻŦāĻ abnormal discharge āĻŦāĻž odour āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
B. Trichomoniasis
Trichomonas vaginalis genital mucosa-āϤ⧠inflammatory response āϏā§āώā§āĻāĻŋ āĻāϰā§āĨ¤
āĻāϤ⧠genital irritation, discharge āĻāĻŦāĻ dysuria āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
C. Candida Vaginitis
Candida species-āĻāϰ āĻ āϤāĻŋāĻŦā§āĻĻā§āϧāĻŋ vulvovaginal inflammation āϏā§āώā§āĻāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϏāĻžāϧāĻžāϰāĻŖāϤ itching, soreness āĻāĻŦāĻ external dysuria āĻŦā§āĻļāĻŋ āĻĻā§āĻāĻž āϝāĻžā§āĨ¤
D. Acute Cystitis
Uropathogenic bacteria urethra āĻĻāĻŋā§ā§ bladder-āĻ āĻĒā§āϰāĻŦā§āĻļ āĻāϰ⧠infection āϤā§āϰāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
E. Noninfectious Irritation
Perfumed soap, antiseptic wash, lubricants āĻŦāĻž contact allergens-āĻ vaginal burning āϏā§āώā§āĻāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical point: āĻāĻāĻ āĻāĻĒāϏāϰā§āĻā§āϰ āĻāĻāĻžāϧāĻŋāĻ āĻāĻžāϰāĻŖ āϏāĻŽā§āĻāĻŦāĨ¤ āϤāĻžāĻ antibiotic selection āĻĻā§āĻā§ āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
13. Clinical Features & Differential Diagnosis
| Disease | Typical clinical clues | Current patient evidence |
|---|---|---|
| Bacterial Vaginosis | Thin discharge, fishy odour, elevated vaginal pH | Burning documented; āĻ āύā§āϝāĻžāύā§āϝ āϤāĻĨā§āϝ āύā§āĻ |
| Trichomoniasis | Irritation, dysuria, discharge | Burning āĻāĻā§; testing āĻšā§āύāĻŋ |
| Candida Vaginitis | Itching, redness, thick discharge | āĻāϏāĻŦ āϤāĻĨā§āϝ āĻāϞā§āϞā§āĻ āύā§āĻ |
| Cervicitis | Cervical discharge, bleeding, cervical inflammation | Examination āύā§āĻ |
| Acute Cystitis | Dysuria, frequency, urgency | Urethral burning āĻāĻā§; frequency/urgency āύā§āĻ |
| Contact Vulvitis | Burning after soap/chemical exposure | Exposure history āύā§āĻ |
| Pelvic Inflammatory Disease | Pelvic pain, fever, pelvic tenderness | Supporting findings āύā§āĻ |
Differential Diagnosis Conclusion
Most defensible diagnosis: Vulvovaginal and urethral burning of undetermined etiologyāĨ¤
Most important infectious conditions to evaluate: BV, Trichomoniasis, Cervicitis, Cystitis āĻāĻŦāĻ CandidiasisāĨ¤
Confidence: 0.95
14. Investigations â āĻā§ āĻā§ āĻĒāϰā§āĻā§āώāĻž āĻĒā§āϰā§ā§āĻāύ?
A. Doctor's Investigations
No clear investigations prescribed in the visible note.
B. My Recommended Investigations
| Investigation | Clinical purpose | āĻŦāĻžāĻāϞāĻž |
|---|---|---|
| Urine R/E | Evaluate urinary inflammation | āĻĒā§āϰāϏā§āϰāĻžāĻŦā§ āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āĻāĻŋāĻšā§āύ |
| Urine Culture & Sensitivity | When UTI is suspected and testing is indicated | āĻā§āĻŦāĻžāĻŖā§ āĻ antibiotic sensitivity |
| Pregnancy Test | If pregnancy is possible | āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āϝāĻžāĻāĻžāĻ |
| Vaginal pH | Support differential diagnosis of vaginitis | āϝā§āύāĻŋāϰ pH āĻĒāϰā§āĻā§āώāĻž |
| Vaginal Wet Mount | Trichomonads, clue cells and yeast | āĻā§āĻŦāĻžāĻŖā§ āĻ āĻā§āώāĻāϤ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻĻā§āĻāĻž |
| KOH Microscopy | Candida evaluation | āĻāϤā§āϰāĻžāĻ āĻĒāϰā§āĻā§āώāĻž |
| Vaginal NAAT | Selected BV/Trichomonas/Candida assessment | āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϏāĻāĻā§āϰāĻŽāĻŖ āĻļāύāĻžāĻā§āϤ |
| Chlamydia/Gonorrhoea NAAT | If STI/cervicitis suspected | āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āĻļāύāĻžāĻā§āϤ |
| CBC | If systemic illness or anaemia suspected | āϰāĻā§āϤ āĻĒāϰā§āĻā§āώāĻž |
| HbA1c / Blood Glucose | If diabetes risk or persistent numbness | āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏ āĻŽā§āϞā§āϝāĻžā§āύ |
| Vitamin B12 | If clinically indicated for paresthesia | āĻāĻŋāĻāĻžāĻŽāĻŋāύ B12 āĻŽā§āϞā§āϝāĻžā§āύ |
Clinical Priority
First: Clinical history āĻāĻŦāĻ vulvovaginal/pelvic examinationāĨ¤
Second: Urinary symptoms āĻ āύā§āϝāĻžā§ā§ urine testingāĨ¤
Third: Discharge āĻŦāĻž STI risk āĻ āύā§āϝāĻžā§ā§ vaginal microscopy/NAATāĨ¤
Fourth: Hand numbness-āĻāϰ āĻĒā§āĻĨāĻ neurological assessmentāĨ¤
CDC āĻŦāϞāĻā§, āĻļā§āϧ⧠history āĻĻāĻŋā§ā§ vaginitis-āĻāϰ āϏāĻ āĻŋāĻ āĻāĻžāϰāĻŖ āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻ āύā§āĻ āĻā§āώā§āϤā§āϰ⧠āϏāĻŽā§āĻāĻŦ āύā§; examination āĻāĻŦāĻ āĻĒā§āϰā§ā§āĻāύā§ā§ laboratory testing āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Investigation plan confidence: 0.97
15. Guideline-Based Management & Critical Prescription Review
A. Current Prescription Review
Xionil 3 mg
Reasonable only if: Anxiety, tension āĻ āĻĨāĻŦāĻž āĻāĻĒāϝā§āĻā§āϤ āĻ āύā§āϝ indication āĻĨāĻžāĻā§āĨ¤
Concern: Sedation, dependence āĻāĻŦāĻ withdrawal riskāĨ¤
Zithrox 500 mg
Reasonable only if: Susceptible bacterial infection-āĻāϰ āϝāĻĨāĻžāϝāĻĨ indication āĻĨāĻžāĻā§āĨ¤
Concern: 500 mg daily for seven daysâāĻŦāϰā§āϤāĻŽāĻžāύ suspected genital infection-āĻāϰ āĻā§āύ diagnosis āĻ āύā§āϝāĻžā§ā§ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§, āϤāĻž āĻĒāϰāĻŋāώā§āĻāĻžāϰ āύā§āĨ¤
Riboflavine 5 mg
Reasonable if: Vitamin B2 deficiency āĻŦāĻž supplementation-āĻāϰ āĻāĻĒāϝā§āĻā§āϤ āĻāĻžāϰāĻŖ āĻĨāĻžāĻā§āĨ¤
Concern: Hand numbness-āĻāϰ āĻŽā§āϞ āĻāĻžāϰāĻŖ āĻ āĻāĻžāύāĻžāĨ¤
Ornil 500 mg
Reasonable only if: Suitable anaerobic/protozoal infection-āĻāϰ indication āĻĨāĻžāĻā§āĨ¤
Concern: Duration unspecified, āĻāĻŦāĻ āϰā§āĻā§āϰ āĻāĻā§ āĻĨā§āĻā§āĻ numbness āϰā§ā§āĻā§āĨ¤
Three Main Weak Points in the Prescription
1. No definite infectious diagnosis.
āĻŦāĻžāĻāϞāĻž: āĻā§āύ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāύā§āϝ antibiotic āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§, āϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
2. Zithrox regimen requires indication-specific review.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāϤ āĻĻāĻŋāύā§āϰ Azithromycin regimen āĻā§āύ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§, āϤāĻž āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
3. Ornidazole duration is undefined despite neurological symptoms.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻ āĻŦāĻļāĻāĻžāĻŦ āĻĨāĻžāĻāĻž āĻ āĻŦāϏā§āĻĨāĻžā§ Ornidazole āĻāϤāĻĻāĻŋāύ āĻāϞāĻŦā§ āϤāĻž āϏā§āĻĒāώā§āĻ āύāĻž āĻšāĻā§āĻž āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ safety concernāĨ¤
B. If Bacterial Vaginosis Is Confirmed
CDC-recommended regimen-āĻāϰ āĻāĻāĻāĻŋ:
Metronidazole 500 mg orally twice daily for seven days.
āĻāĻāĻžā§āĻž vaginal metronidazole gel āĻ āĻĨāĻŦāĻž clindamycin cream-āĻāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ regimen āϰā§ā§āĻā§āĨ¤
āĻāĻāĻŋ Ornil-āĻāϰ āϏāĻā§āĻā§ āĻāĻāϏāĻā§āĻā§ āϝā§āĻ āĻāϰāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āύā§āĨ¤ āϰā§āĻā§āϰ history, pregnancy status āĻ contraindications āĻ āύā§āϝāĻžā§ā§ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
C. If Trichomoniasis Is Confirmed
CDC āĻ āύā§āϝāĻžā§ā§ āύāĻžāϰā§āĻĻā§āϰ āĻāύā§āϝ:
Metronidazole 500 mg orally twice daily for seven days.
Sexual partner evaluation āĻ treatment āĻĒā§āϰā§ā§āĻāύāĨ¤
Treatment āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻšāĻā§āĻž āĻāĻŦāĻ symptoms resolve āύāĻž āĻšāĻā§āĻž āĻĒāϰā§āϝāύā§āϤ intercourse āĻā§āĻŋā§ā§ āĻāϞāĻžāϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ āĻĻā§āĻā§āĻž āĻšā§āĨ¤
D. If Candida Infection Is Confirmed
Topical azole therapy āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžā§āĨ¤
Nonpregnant uncomplicated candidiasis-āĻāϰ āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āĻā§āώā§āϤā§āϰ⧠oral fluconazole āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšā§āĨ¤
Pregnancy: CDC āĻ āύā§āϝāĻžā§ā§ āϏāĻžāϤ āĻĻāĻŋāύā§āϰ topical azole therapy āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ; oral fluconazole routine treatment āĻšāĻŋāϏā§āĻŦā§ āϏā§āĻĒāĻžāϰāĻŋāĻļ āĻāϰāĻž āĻšā§ āύāĻžāĨ¤
E. If Acute Cystitis Is Confirmed
NICE NG109 āĻ āύā§āϝāĻžā§ā§ nonpregnant women-āĻāϰ āĻā§āώā§āϤā§āϰ⧠nitrofurantoin āĻ āĻĨāĻŦāĻž āĻāĻĒāϝā§āĻā§āϤ āĻ āύā§āϝ antibiotic āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžā§āĨ¤
Renal function, pregnancy, bacterial susceptibility āĻāĻŦāĻ local resistance āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
F. If Cervicitis Is Diagnosed
Chlamydia āĻ Gonorrhoea testing āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
CDC guideline āĻ āύā§āϝāĻžā§ā§ āĻāĻĒāϝā§āĻā§āϤ nonpregnant patients-āĻāϰ āĻāύā§āϝ doxycycline-based treatment standard optionāĨ¤
Clinical management confidence: 0.97
16. Real Prescription Demo â Clinical Working Assessment
This is a documentation example, not a new treatment prescription.
LIPU MED â GYNECOLOGY CLINICAL NOTE
Patient: Female; age not verified
Original Visit: 21 April 2025
C/C:
Pain and burning sensation in vaginal and urethral region.
Numbness in hand.
M/H:
LMP approximately 10/04/2025.
Menstrual duration six days.
Regular cycle.
Average menstrual flow.
No documented dysmenorrhoea.
O/H:
P3, NVD Ã 3 â to verify.
Past H/O:
Cervical Erosion.
D&C/ECC â procedure details and histopathology report unavailable.
O/E:
Weight approximately 81 kg.
BP approximately 100/80 mmHg.
Pelvic examination findings not documented.
đĒ Provisional Diagnosis
Vulvovaginal and Urethral Burning/Pain â Etiology Undetermined; Suspected Vulvovaginitis; R/O Bacterial Vaginosis, Trichomoniasis, Cervicitis and Acute Cystitis. Associated Hand Paresthesia.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻŋāĻĒāĻĨ āĻ āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϤ⧠āĻŦā§āϝāĻĨāĻž āĻ āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž; āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϝā§āύāĻŋāĻĒāĻĨā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āĻā§āϝāĻžāĻāĻžāĻāύā§āϏāĻŋāϏ, āĻā§āϰāĻžāĻāĻā§āĻŽā§āύāĻŋā§āĻžāϏāĻŋāϏ, āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŦāĻ āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻā§ āĻāĻŋ āύāĻž āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύāĨ¤ āϏāĻā§āĻā§ āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦāĨ¤
Original Prescription â Corrected Transcription
| Medicine | Dose | Duration |
|---|---|---|
| Tab. Xionil 3 mg | 0+0+1 | 15 days |
| Tab. Zithrox 500 mg | 0+0+1 | 7 days |
| Tab. Riboflavine 5 mg | 1+0+1 | 1 month |
| Tab. Ornil 500 mg | 1+0+1 | To be continued â duration clarification required |
Important: āĻāĻ āĻāώā§āϧāĻā§āϞ⧠⧍ā§Ļ⧍ā§Ģ āϏāĻžāϞā§āϰ prescription-āĻāϰ historical transcriptionāĨ¤ ⧍ā§Ļ⧍ā§Ŧ āϏāĻžāϞ⧠āύāϤā§āύ āĻāϰ⧠āĻļā§āϰ⧠āĻŦāĻž āĻāĻžāϞāĻŋā§ā§ āϝāĻžāĻā§āĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Investigation Plan
Clinical assessment āĻ āύā§āϝāĻžā§ā§ urine testing, vaginal examination, wet mount/NAAT āĻāĻŦāĻ āĻĒā§āϰā§ā§āĻāύā§ā§ STI testingāĨ¤
Review Plan
Clarify the indication for both antimicrobial agents and the stop date of Ornidazole.
Assess hand numbness and relevant neurological risk before considering prolonged nitroimidazole exposure.
Referral
Consultant Obstetrician & Gynaecologist
Additional Medicine/Neurology consultation if paresthesia persists or progressesāĨ¤
17. Final Clinical Assessment
Overview / Summary
āĻāĻ āϰā§āĻā§āϰ āĻĒā§āϰāϧāĻžāύ documented āϏāĻŽāϏā§āϝāĻž āĻšāϞ⧠āϝā§āύāĻŋāĻĒāĻĨ āĻ āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϤ⧠āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻžāĨ¤ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āϰā§ā§āĻā§āĨ¤
āĻĒā§āϰā§āĻŦā§ Cervical Erosion āĻāĻŦāĻ D&C/ECC-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāϞā§āϞā§āĻ āĻāĻā§āĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻ āĻāĻžāϰāĻāĻŋ āĻāώā§āϧ āĻĻāĻŋā§ā§āĻā§āύ:
Xionil â Bromazepam: āĻāĻĻā§āĻŦā§āĻ āĻŦāĻž āϏāĻāĻļā§āϞāĻŋāώā§āĻ āĻāĻĒāϏāϰā§āĻ āĻāĻŽāĻžāύā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĻā§āĻĻā§āĻļā§āϝāĨ¤
Zithrox â Azithromycin: āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ bacterial infection-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĻā§āĻĻā§āĻļā§āϝāĨ¤
Riboflavine â Vitamin B2: nutritional supplementation-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĻā§āĻĻā§āĻļā§āϝāĨ¤
Ornil â Ornidazole: anaerobic/protozoal genital infection-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
āϤāĻŦā§ drug selection āĻĨā§āĻā§ definitive diagnosis āϤā§āϰāĻŋ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
Final Confidence Table
| Conclusion | Confidence |
|---|---|
| Corrected drug identification | 1.00 |
| Corrected dosing transcription | 1.00 |
| Vaginal/urethral symptoms documented | 0.98 |
| Hand numbness documented | 0.96 |
| Previous cervical procedure history | 0.85 |
| Suspected vulvovaginal inflammation | 0.75 |
| BV is a possible cause | 0.60 |
| Trichomoniasis is a possible cause | 0.50 |
| Cervicitis is a possible cause | 0.50 |
| Cystitis is a possible cause | 0.55 |
| Need to clarify prolonged Ornil use | 0.98 |
| Definitive laboratory-confirmed diagnosis | Not established |
Final Diagnostic Statement
Vulvovaginal and Urethral Burning/Pain of Undetermined Etiology, with Suspected Vulvovaginitis; Evaluate for Bacterial Vaginosis, Trichomoniasis, Cervicitis and Acute Cystitis. Associated Hand Paresthesia. H/O Cervical Erosion and D&C/ECC.
āĻŦāĻžāĻāϞāĻž: āϝā§āύāĻŋāĻĒāĻĨ āĻ āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϤ⧠āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž, āϝāĻžāϰ āϏāĻ āĻŋāĻ āĻāĻžāϰāĻŖ āĻāĻāύāĻ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻšā§āύāĻŋāĨ¤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϝā§āύāĻŋāĻĒāĻĨā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āϰā§ā§āĻā§āĨ¤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āĻā§āϝāĻžāĻāĻžāĻāύā§āϏāĻŋāϏ, āĻā§āϰāĻžāĻāĻā§āĻŽā§āύāĻŋā§āĻžāϏāĻŋāϏ, āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŦāĻ āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻĒāϰā§āĻā§āώāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āϰā§ā§āĻā§ āĻāĻŦāĻ āĻĒā§āϰā§āĻŦā§ Cervical Erosion āĻ D&C/ECC-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻā§āĨ¤
Actionable Clinical Plan
Step 1: āϰā§āĻā§āϰ vaginal symptoms āĻ urinary symptoms āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ history āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
Step 2: Pregnancy possibility, medication allergy āĻāĻŦāĻ current medication history āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 3: āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ vulval āĻ speculum examination āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 4: Urinary symptoms āĻĨāĻžāĻāϞ⧠Urine R/E Âą Culture āĻāĻŦāĻ vaginal symptoms āĻ āύā§āϝāĻžā§ā§ vaginal testing āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 5: Azithromycin āĻ Ornidazole āĻĻā§āĻā§āĻžāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ indication āĻāĻŦāĻ duration āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 6: āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āĻĨāĻžāĻāĻžā§ neurological assessment āĻāϰāϤ⧠āĻšāĻŦā§, āĻŦāĻŋāĻļā§āώāϤ prolonged Ornidazole āĻŦāĻŋāĻŦā§āĻāύāĻžāϰ āĻāĻā§āĨ¤
Step 7: āĻĒā§āϰā§āĻŦā§āϰ D&C/ECC-āĻāϰ procedure note āĻ histopathology report āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 8: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ diagnosis āĻĒāĻžāĻā§āĻž āĻā§āϞ⧠guideline-based targeted treatment āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 9: Follow-up-āĻ symptoms, examination findings āĻāĻŦāĻ treatment response documented āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Reference List
A. Medical Textbooks
- Harrison's Principles of Internal Medicine. 21st edition. McGraw Hill. Relevant sections: Urinary Tract Infections, Peripheral Neuropathy and Clinical Evaluation of Dysuria.
- Williams Gynecology. 4th edition. McGraw Hill. Relevant chapters: Lower Genital Tract Infections, Cervical Disorders and Gynecologic Examination.
- Berek & Novak's Gynecology. 16th edition. Wolters Kluwer. Relevant sections: Vulvovaginal Infections and Cervical Disease.
- Dutta's Textbook of Gynecology. 8th edition. Jaypee Brothers. Relevant chapters: Vaginal Discharge and Cervical Disorders.
- Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th edition. McGraw Hill. Relevant chapters: Antibacterial Drugs, Antiprotozoal Drugs and Sedative-Hypnotics.
- Katzung's Basic & Clinical Pharmacology. 16th edition. McGraw Hill. Relevant chapters: Benzodiazepines, Macrolides, Nitroimidazoles and Vitamins.
Textbook page numbers have not been independently verified and are not supplied.
B. Clinical Guidelines
- CDC. Sexually Transmitted Infections Treatment Guidelines, 2021. Vulvovaginal symptoms, Bacterial Vaginosis, Trichomoniasis, Candidiasis and Cervicitis.
- NICE Guideline NG109. Urinary Tract Infection (Lower): Antimicrobial Prescribing. Published 2018.
- MedEx Bangladesh. Verified monographs of Xionil 3 mg, Zithrox 500 mg, Riboflavine 5 mg and Ornil 500 mg.
C. Peer-Reviewed Journals With DOI
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1â187. DOI: 10.15585/mmwr.rr7004a1.
- Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does This Woman Have an Acute Uncomplicated Urinary Tract Infection? JAMA. 2002;287(20):2701â2710. DOI: 10.1001/jama.287.20.2701.
LIPU MED â Author Information
Author Name: Md.Rafiqul Islam Lipu
Date: Thursday, 15 October 2026
Time: 9:16 PM â Bangladesh Standard Time (UTC+06:00)
Website: raiyyantahsan.com
Final Prescription-Ready Provisional Dx:
Suspected Vulvovaginitis with Vaginal/Urethral Burning; R/O BV, Trichomoniasis, Cervicitis and Acute Cystitis; Associated Hand Paresthesia; H/O Cervical Erosion and D&C/ECC.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϝā§āύāĻŋāĻĒāĻĨā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻ āϝā§āύāĻŋ-āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϤ⧠āĻā§āĻŦāĻžāϞāĻžāĻĒā§ā§āĻž; āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϞ āĻā§āϝāĻžāĻāĻžāĻāύā§āϏāĻŋāϏ, āĻā§āϰāĻžāĻāĻā§āĻŽā§āύāĻŋā§āĻžāϏāĻŋāϏ, āĻāϰāĻžā§ā§āĻŽā§āĻ āĻ āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύ; āϏāĻā§āĻā§ āĻšāĻžāϤ⧠āĻ āĻŦāĻļāĻāĻžāĻŦ āĻāĻŦāĻ āĻĒā§āϰā§āĻŦā§ āĻāϰāĻžā§ā§āĻŽā§āĻā§āϰ āϏāĻŽāϏā§āϝāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤